First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

FDA-approved drug may finally help immunotherapy defeat rare liver cancer

Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

Manganese perovskite nanocubes convert cold tumors to hot in hepatocellular carcinoma via PANoptosis/STING activation

This article presents a novel nanosystem for treating hepatocellular carcinoma (HCC) by converting immunologically "cold" tumors into "hot"

Nanoplatform co-delivering H2S and Ni2+ reverses chemoresistance and enhances immunotherapy in breast cancer

This research article presents a study on a novel nanoplatform (NiS@ALB) designed to combat chemoresistance in breast cancer. The authors de

Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial

Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic